Search the Newsreel

Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter

Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen

Wall Street Zen upgraded Alto Neuroscience (NYSE:ANRO) from "strong sell" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with a target price of $36.62. Shares opened at $32.14, near their 12-month high, and the company reported a quarterly loss of $0.65 …

Is Cadence Design Systems (CDNS) Undervalued As It Raises Its 2026 Outlook?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Why Cadence Design Systems Stock Is Back in Focus Cadence Design Systems (CDNS) is …

Is Cadence Design Systems (CDNS) Stock Too Rich To Stay Reasonable?

Indogulf Cropsciences Q1FY27 net profit down 38% YoY; EBITDA margin rises to 6%

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com

Skye Bioscience announced its definitive agreement to acquire Redx Pharma through a scheme of arrangement under U.K. law for an approximate $125 million deal. The merged entity will be known as Fibrx Therapeutics Inc., trading on Nasdaq, and will be led by Redx's current …

Wave Life Sciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043

Cadence (CDNS) Stock Gets Fair Value Bump As Analysts Lift Targets After Q2

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Cadence Design Systems is back in focus as analysts lift price targets into a US$400 to US$450 range, reflecting a slightly higher Fair …

TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA

TuHURA Biosciences anticipates preliminary results from its IFX-2.0 study, which combines IFX-2.0 with Keytruda for treating deep-seated Merkel Cell Carcinoma (MCC). These results are expected in the first half of 2027. This study represents a key milestone for TuHURA Biosciences in its development of …

Has Cadence Design Systems (CDNS) Stock Become Priced For Perfection?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cadence Design Systems stock has more than doubled over the past five years, yet the current checks point to a rich valuation that …

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …

Bright Minds Biosciences (NASDAQ:DRUG) Issues Quarterly Earnings Results

Bright Minds Biosciences (NASDAQ:DRUG) reported quarterly earnings per share of ($0.17), significantly surpassing analysts' consensus estimate of ($1.28). Following the announcement, shares fell 2.0% to $76.44. Analysts maintain a generally positive outlook on the stock, with an average "Buy" rating and a consensus price …

Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF Value Says Undervalued

Castle Biosciences Inc (CSTL) shares recently dropped 3.0%, leading to a 7.5% decrease over the past week, but GuruFocus' GF Value indicates the stock is slightly undervalued. Despite a strong GF Score of 81/100, driven by high growth potential, the company faces significant challenges …

These Analysts Revise Their Forecasts On Legence Following Q2 Results

Legence Corp (NASDAQ: LGN) reported mixed second-quarter results, missing earnings estimates but exceeding sales expectations. Following the announcement, BTIG analyst Gregory Lewis reiterated a Buy rating but lowered the price target from $120 to $100, while BMO Capital analyst Devin Dodge maintained an Outperform …

UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80

UBS has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained its target price at $80. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.

Perceptive Advisors (NASDAQ: SLDB) details 11.2% beneficial stake and warrant limits

Perceptive Advisors LLC and related entities, including Joseph Edelman, have reported a beneficial ownership of 12,046,579 shares in Solid Biosciences Inc. (NASDAQ: SLDB), representing an 11.2% stake. This includes common stock and pre-funded warrants, with the latter subject to a 9.99% beneficial ownership limitation …

TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS

CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ

A holder of CSTL common stock has filed a notice of intent to sell up to 24,908 shares on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services. The indicated aggregate market value of these shares is $741,493.72, and they originated from restricted …

Tencent Holdings (SEHK:700) Backs AI Startup As Global AI Push Picks Up

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Tencent Holdings (SEHK:700) is ramping up its global AI efforts with a significant investment in Swedish AI coding startup Lovable. The company is …

Legence (LGN) Stock Jumps As Backlog Strength Recasts Loss Concerns

Assembly Biosciences (ASMB) Stock Jumps As Losses Shrink And Revenue Builds

MCDONALDS CORP (MCD) president Anderson Skye details options, PRSUs and stock

Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100

Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling …

Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility

Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap

An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …

Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …

Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 2.5% beneficial ownership stake in Spruce Biosciences, Inc. (SPRB) through a SCHEDULE 13G/A filing. This stake, totaling 67,717 shares, is held across various managed accounts, with both parties exercising shared voting and dispositive power. …

Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors

Edwards Lifesciences Corp. (EW) stock fell 1.04% on Friday, closing at $91.60. This underperformance occurred on a generally negative trading day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock experienced its third …

Diana Shipping withdraws Genco bid as takeover terms hit a roadblock

Bjoern Wylezich Diana Shipping (DSX [https://seekingalpha.com/symbol/DSX]) announced on Friday that it has withdrawn its offer to acquire the remaining shares of Genco Shipping & Trading (GNK [https://seekingalpha.com/symbol/GNK]) after the companies failed to agree on deal terms. The company's withdrawn offer [https://seekingalpha.com/pr/20620174-diana-shipping-inc-withdraws-offer-to-acquire-genco-shipping-and-trading-following-genco] included $24.80 in …

TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake

New Providence Acquisition III (NASDAQ: NPAC) details Abra merger plan and going-concern risks

New Providence Acquisition III (NPAC) has detailed its merger plan with Abra Financial Holdings and disclosed going-concern risks in its latest quarterly report. The SPAC reported a Q2 2026 net income of $2.24 million, primarily from trust investments, but faces substantial doubt about its …

Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake

Paradigm BioCapital, along with its related entities and Senai Asefaw, M.D., has reported a collective beneficial ownership of 7.8% in Assembly Biosciences (ASMB), totaling 1,553,748 shares. This stake is based on an amended Schedule 13G filing, with Paradigm BioCapital International Fund Ltd. directly holding …

Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax

Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, …

Wheels Up (UP): Whitebox reports 2.8% stake and ends Kore ownership group

Whitebox Advisors LLC and Whitebox General Partner LLC have reported an updated ownership stake in Wheels Up Experience Inc. As of June 30, 2026, Whitebox beneficially owns 1,021,597 shares of Class A Common Stock, representing approximately 2.8% of the outstanding shares. The filing also …

Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap

A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The …

Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Vestal Point Capital, along with its Chief Investment Officer Ryan Wilder, has reported a beneficial ownership of 4.8% in Solid Biosciences Inc. (SLDB). This stake includes 4,833,796 common shares, of which 2,673,796 are issuable upon the exercise of pre-funded common stock purchase warrants. The …